1. P383 One-year experience with ustekinumab in therapy-refractory or -intolerant patients with ulcerative colitis. (25th January 2019) Authors: Ochsenkühn, T; Tillack, C; Schnitzler, F; Szokodi, D; Janelidze, S Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S298 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P759 Ustekinumab as rescue treatment in therapy-refractory or -intolerant ulcerative colitis. (16th January 2018) Authors: Ochsenkühn, T; Janelidze, S; Tillack, C; Beigel, F Journal: Journal of Crohn's and colitis Issue: Volume 12:Number 1(2018:Jan.)Supplement 1 Page Start: S495 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. PO.1.13 Plasma and cerebrospinal fluid neurofilament light concentrations reflect neuronal damage in systemic lupus erythematosus. (27th September 2022) Authors: Zervides, KA; Janelidze, S; Nystedt, J; Gullstrand, B; Nilsson, P; Sundgren, PC; Bengtsson, AA; Hansson, O; Jönsen, A Journal: Lupus science & medicine Issue: Volume 9(2022)Supplement 2 Page Start: A29 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗